6 RESEARCH Index

| |
|---|
| 6.0 Summary Research Findings Index.pdf |
| 6.1.1 Aerosol Chemistry.pdf |
| 6.1.2 Pre-Clinical Safety.pdf |
| 6.1.3.1 Justification of BoExp selection.pdf |
| 6.1.3.2 Summary of BoExp Assessment.pdf |
| 6.1.3.3 Bioanalytical Methods.pdf |
| 6.1.3.4 REX Overview of Studies.pdf |
| 6.1.4 CRE.pdf |
| 6.1.5 Human Safety Summary.pdf |
| 6.1.6 Conclusion.pdf |
| 6.2.1.1 Summary of Clinical Pharmacology Studies.pdf |
| 6.2.1.2 PKPD Overview of Studies.pdf |
| 6.2.2 Product Usage.pdf |
| 6.2.3 Abuse Liability.pdf |
| 6.2.4 Conclusion.pdf |
| 6.3.1 Intent to Use among non-users.pdf |
| 6.3.2 Epidemiological Evidence .pdf |
| 6.3.3 Conclusion.pdf |
| 6.4 Consumer Understanding and Perceptions.pdf |
| 6.5 Effect on the population as a whole.pdf |
| A6.1.3.1 Factsheet Carbon Monoxide.pdf |
| A6.1.3.10 Factsheet 2-NA.pdf |
| A6.1.3.11 Factsheet 4-ABP.pdf |
| A6.1.3.12 Factsheet o-Toluidine.pdf |
| A6.1.3.13 Factsheet NNK.pdf |
| A6.1.3.14 Factsheet NNN_2.pdf |
| A6.1.3.15 Factsheet BaP.pdf |

6 RESEARCH Index

| |
|---|
| A6.1.3.16 Factsheet Pyrene.pdf |
| A6.1.3.17 Factsheet Nicotine.pdf |
| A6.1.3.18 Factsheet CYP2A6.pdf |
| A6.1.3.19 Factsheet CYP1A2_2.pdf |
| A6.1.3.2 Factsheet 1_3-Butadiene.pdf |
| A6.1.3.20 Factsheet Urine mutagenicity.pdf |
| A6.1.3.21 Factsheet Isoprene.pdf |
| A6.1.3.22 Factsheet Formaldehyde.pdf |
| A6.1.3.23 Factsheet Acetaldehyde.pdf |
| A6.1.3.24 Factsheet Acrylamide.pdf |
| A6.1.3.25 Factsheet Ammonia.pdf |
| A6.1.3.26 BoExp Non-clinical results.pdf |
| A6.1.3.27 Summary AA33664-01.pdf |
| A6.1.3.28 Summary AA33664-06.pdf |
| A6.1.3.29 Summary AA33664-07.pdf |
| A6.1.3.3 Factsheet Acrolein.pdf |
| A6.1.3.30 Summary AA33664-08.pdf |
| A6.1.3.31 Summary ZZ36536-01.pdf |
| A6.1.3.32 Summary ZZ34313-03.pdf |
| A6.1.3.33 Summary ZZ38073-01.pdf |
| A6.1.3.34 Summary ZZ33881-03.pdf |
| A6.1.3.35 Summary ZZ33881-04.pdf |
| A6.1.3.36 Summary ZZ42666-01.pdf |
| A6.1.3.37 Summary ZZ25187-02.pdf |
| A6.1.3.38 Summary ZZ37540-01.pdf |
| A6.1.3.39 Summary VAA98876-02.pdf |
| A6.1.3.4 Factsheet Crotonaldehyde.pdf |

6 RESEARCH Index

| |
|---|
| A6.1.3.40 Summary VAA98876-03.pdf |
| A6.1.3.41 Summary VAA98876-01.pdf |
| A6.1.3.5 Factsheet Acrylonitrile.pdf |
| A6.1.3.6 Factsheet Ethylene Oxide.pdf |
| A6.1.3.7 Factsheet Benzene.pdf |
| A6.1.3.8 Factsheet Toluene.pdf |
| A6.1.3.9 Factsheet 1-NA.pdf |
| A6.1.4.1 WBC count.pdf |
| A6.1.4.10 Apo_A1.pdf |
| A6.1.4.11 Oxysterols.pdf |
| A6.1.4.12 HbA1c.pdf |
| A6.1.4.13 FEV1.pdf |
| A6.1.4.2 CRP.pdf |
| A6.1.4.3 sICAM.pdf |
| A6.1.4.4 Fibrinogen.pdf |
| A6.1.4.5 8_iso_PGF2alpha.pdf |
| A6.1.4.6 Thromboxane B TXB2.pdf |
| A6.1.4.7 COHb.pdf |
| A6.1.4.8 HDL_C.pdf |
| A6.1.4.9 LDL_C.pdf |
| A6.1.5.1 THS variants and Safety.pdf |
| A6.1.5.2 Safety population.pdf |
| A6.1.5.3 SAE ICSRs.pdf |
| A6.1.5.4 AE clinical.pdf |
| A6.1.5.5 Pharmacotherapies safety.pdf |
| A6.1.5.6 Premarket safety surveillance.pdf |
| A6.2.2.1 HPT and Use patterns Tables REXA_2.pdf |

6 RESEARCH Index

| |
|---|
| A6.2.2.2 WOT Transition Tables.pdf |
| A6.2.3.1 Sanders Manuscript.pdf |